The market for Psoriatic Arthritis Treatment Market is expected to reach USD$ XX billion in 2026.
The Arthritis Foundation defines psoriatic arthritis as an autoimmune inflammatory disease that primarily affects the skin. The majority of psoriasis patients develop psoriatic arthritis in the later stages of the disease. Psoriatic arthritis affects men and women equally, with a global prevalence rate of 6 per 100,000 people. It is a diverse disease with five subtypes: symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans. The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors. The occurrence is highest in the Caucasian populations of North America and Europe, followed by Asia and the Pacific.
According to the International Federation of Psoriasis Associations (IFPA) 2016 statistics, around 125 million people throughout the globe are suffering from psoriatic arthritis. The diagnosis of psoriatic arthritis is complex due to the presence of symptoms in patients such as tendinitis, inflammatory spinal pain, or dactylitis, which are most often misunderstood as arthritis. Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease, such as mild, moderate, or severe psoriatic arthritis. The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab has improved drug safety and efficacy for the treatment of psoriatic arthritis. ABT-494 (Abbvie, Inc.), Aprelimast (Celgene Corporation), and Certolizumab Pegol (UCB BIOSCIENCES GmbH) are being developed as targeted therapies and are set to launch during the forecast period from 2018 to 2026 and capitalize on the psoriatic arthritis treatment market.
Mechanism of Action
Geography
Abbvie, Inc.; Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La-Roche AG; Janssen Global Services; Merck & Co.; Novartis AG; Valeant Pharmaceuticals International, Inc.
The market for Psoriatic Arthritis Treatment Market is expected to reach USD$ XX billion in 2026.
The Psoriatic Arthritis Treatment Market is expected to see significant CAGR growth over the coming years, at XX%.
The report is forecasted from 2018 -2026.
The base year of this report is 2017.
Abbvie, Inc.; Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La-Roche AG; Janssen Global Services; Merck & Co. are some of the major players in the global market.